Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice

European Journal of Pharmacology

Volumn 674, Issue 2-3, 2012, Pages 294-306

  Faivre, Emilie ^a   Hamilton, Alison ^a   Hölscher, Christian ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Alzheimer's disease; Diabetes; Learning and memory; Neurogenesis; Stem cell

Indexed keywords

DEXTRO 2 ALANINE GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; PROLINE 3 GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL PROLIFERATION; CHRONIC DRUG ADMINISTRATION; COGNITION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DENTATE GYRUS; DOSE RESPONSE; HIPPOCAMPAL CA1 REGION; LEARNING; LONG TERM POTENTIATION; MALE; MAZE TEST; MEMORY; MEMORY DISORDER; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RECOGNITION;

ANIMALS; CA1 REGION, HIPPOCAMPAL; CELL PROLIFERATION; COGNITION; DENTATE GYRUS; EXPLORATORY BEHAVIOR; GASTRIC INHIBITORY POLYPEPTIDE; LONG-TERM POTENTIATION; MALE; MEMORY; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEURAL STEM CELLS; NEUROGENESIS; NEURONAL PLASTICITY; RECEPTORS, GASTROINTESTINAL HORMONE; SYNAPSES; TIME FACTORS;

EID: 84855544372     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.11.007     Document Type: Article

References (36)

1. Abbas, T., Faivre, E., Holscher, C., 2009. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res. 205, 265-271.
2. Baggio, L.L., Drucker, D.J., 2007. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157. (Pubitemid 46711096)
3. Blurton-Jones, M., Kitazawa, M., Martinez-Coria, H., Castello, N.A., Muller, F.J., Loring, J.F., Yamasaki, T.R., Poon, W.W., Green, K.N., LaFerla, F.M., 2009. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 106, 13594-13599.
4. Buhren, B.A., Gasis, M., Thorens, B., Muller, H.W., Bosse, F., 2009. Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth. J. Neurosci. Res. 87, 1858-1870.
5. Deacon, C.F., 2004. Circulation and degradation of GIP and GLP-1. Horm. Metab. Res. 36, 761-765. (Pubitemid 40115896)
6. Dere, E., Huston, J.P., De Souza Silva, M.A., 2007. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci. Biobehav. Rev. 31, 673-704. (Pubitemid 46670336)
7. Ding, K.H., Zhong, Q., Xie, D., Chen, H.X., Della-Fera, M.A., Bollag, R.J., Bollag, W.B., Gujral, R., Kang, B., Sridhar, S., Baile, C., Curl, W., Isales, C.M., 2006. Effects of glucose-dependent insulinotropic peptide on behavior. Peptides 27, 2750-2755. (Pubitemid 44739954)
8. Drucker, D.J., Nauck, M.A., 2006. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705. (Pubitemid 46048557)
9. Ennaceur, A., 2009. One-trial object recognition in rats and mice: methodological and theoretical issues. Behav. Brain Res. 215, 244-254.
10. Faivre, E., Gault, V.A., Thorens, B., Holscher, C., 2011. Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. J. Neurophysiol. 105, 1574-1580.
11. Figueiredo, C.P., Pamplona, F.A., Mazzuco, T.L., Aguiar Jr., A.S., Walz, R., Prediger, R.D., 2010. Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases. Behav. Pharmacol. 21, 394-408.
12. Gault, V.A., Holscher, C., 2008. Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. J. Neurophysiol. 99, 1590-1595. (Pubitemid 351550057)
13. Gault, V.A., O'Harte, F.P., Harriott, P., Mooney, M.H., Green, B.D., Flatt, P.R., 2003. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 46, 222-230. (Pubitemid 36343886)
14. Gault, V.A., Irwin, N., Green, B.D., McCluskey, J.T., Greer, B., Bailey, C.J., Harriott, P., O'Harte, F.P., Flatt, P.R., 2005. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54, 2436-2446. (Pubitemid 41134273)
15. Gault, V.A., Kerr, B.D., Irwin, N., Flatt, P.R., 2008. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. Biochem. Pharmacol. 75, 2325-2333.
16. Gengler, S., McClean, P.L., McCurtin, R., Gault, V.A., Holscher, C., 2012. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging. 33, 265-276.
17. Green, B.D., Gault, V.A., Flatt, P.R., Harriott, P., Greer, B., O'Harte, F.P., 2004. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch. Biochem. Biophys. 428, 136-143. (Pubitemid 38891556)
18. Hansotia, T., Baggio, L.L., Delmeire, D., Hinke, S.A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J.J., Schuit, F., Drucker, D.J., 2004. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53, 1326-1335. (Pubitemid 38569020)
19. Hinke, S.A., Manhart, S., Pamir, N., Demuth, H., R., W.G., Pederson, R.A., McIntosh, C.H., 2001. Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP). Biochim. Biophys. Acta 1547, 143-155.
20. Hinke, S.A., Gelling, R.W., Pederson, R.A., Manhart, S., Nian, C., Demuth, H.U., McIntosh, C.H., 2002. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 51, 652-661. (Pubitemid 34760172)
21. Holscher, C., 2010. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat. CNS Drug Discov. 5, 109-117.
22. Hunter, K., Holscher, C., 2011. Liraglutide, (dAla2)GIP and Ac-GIP Cross the Blood Brain Barrier. poster ARUK Conference, Leeds.
23. Irwin, N., Green, B.D., Gault, V.A., Harriot, P., O'Harte, F.P., Flatt, P.R., 2006. Stable agonist of glucose-dependent insulinotropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice. Exp. Gerontol. 41, 151-156. (Pubitemid 43165688)
24. Irwin, N., McClean, P.L., O'Harte, F.P., Gault, V.A., Harriott, P., Flatt, P.R., 2007. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 50, 1532-1540. (Pubitemid 46879021)
25. Li, Y., Perry, T., Kindy, M.S., Harvey, B.K., Tweedie, D., Holloway, H.W., Powers, K., Shen, H., Egan, J.M., Sambamurti, K., Brossi, A., Lahiri, D.K., Mattson, M.P., Hoffer, B.J., Wang, Y., Greig, N.H., 2009. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 106, 1285-1290.
26. McClean, P., Parthsarathy, V., Faivre, E., Hölscher, C., 2011. The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31, 6587-6594.
27. Nyberg, J., Anderson, M.F., Meister, B., Alborn, A.M., Strom, A.K., Brederlau, A., Illerskog, A.C., Nilsson, O., Kieffer, T.J., Hietala, M.A., Ricksten, A., Eriksson, P.S., 2005. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J. Neurosci. 25, 1816-1825. (Pubitemid 40279287)
28. Nyberg, J., Jacobsson, C., Anderson, M.F., Eriksson, P.S., 2007. Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. J. Neurosci. Res. 85, 2099-2119. (Pubitemid 47172142)
29. Pamir, N., Lynn, F.C., Buchan, A.M., Ehses, J., Hinke, S.A., Pospisilik, J.A., Miyawaki, K., Yamada, Y., Seino, Y., McIntosh, C.H., Pederson, R.A., 2003. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am. J. Physiol. Endocrinol. Metab. 284, E931-E939. (Pubitemid 36444028)
30. Pederson, R.A., Satkunarajah, M., McIntosh, C.H., Scrocchi, L.A., Flamez, D., Schuit, F., Drucker, D.J., Wheeler, M.B., 1998. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes 47, 1046-1052. (Pubitemid 28294546)
31. Porter, D.W., Irwin, N., Flatt, P.R., Holscher, C., Gault, V.A., 2010. Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. Eur. J. Pharmacol. 650, 688-693.
32. Preitner, F., Ibberson, M., Franklin, I., Binnert, C., Pende, M., Gjinovci, A., Hansotia, T., Drucker, D.J., Wollheim, C., Burcelin, R., Thorens, B., 2004. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J. Clin. Invest. 113, 635-645. (Pubitemid 38542513)
33. Scrocchi, L.A., Hill, M.E., Saleh, J., Perkins, B., Drucker, D.J., 2000. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. Diabetes 49, 1552-1560.
34. Tian, J.Q., Wang, Y., Lin, N., Guo, Y.J., Sun, S.H., Zou, D.J., 2010. Active immunization with glucose-dependent insulinotropic polypeptide vaccine influences brain function and behaviour in rats. Scand. J. Immunol. 72, 1-7.
35. Trumper, A., Trumper, K., Trusheim, H., Arnold, R., Goke, B., Horsch, D., 2001. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 15, 1559-1570. (Pubitemid 32826409)
36. Usdin, T.B., Mezey, E., Button, D.C., Brownstein, M.J., Bonner, T.I., 1993. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133, 2861-2870. (Pubitemid 24000747)